Ketoflo ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 248 | グルコーストランスポーター1欠損症 | 1 |
248. グルコーストランスポーター1欠損症
臨床試験数 : 29 / 薬物数 : 9 - (DrugBank : 1) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04399954 (ClinicalTrials.gov) | February 24, 2020 | 18/5/2020 | Evaluation of Ketoflo | A Study to Evaluate the Acceptability of Ketoflo, a Food for Special Medical Purposes (FSMP) for Use in the Dietary Management of Epilepsy or Neurometabolic Conditions Requiring a Ketogenic Diet (KD) | Epilepsy Intractable;Glucose Transporter Type 1 Deficiency Syndrome;Ketogenic Dieting | Dietary Supplement: Ketoflo | Vitaflo International, Ltd | NULL | Recruiting | 3 Years | 18 Years | All | 30 | N/A | United Kingdom |